Tom Price bought Biogen Inc (NASDAQ: BIIB)
Tom Price (R-GA), a U.S. Representative, has disclosed 1 trade in Biogen Inc (BIIB) since 2016, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Tom Price bought $1,001 - $15,000 of Biogen Inc (NASDAQ: BIIB) on March 17, 2016. Since that trade, BIIB is down -15.05% against the S&P 500 up +321.76%, an outperformance of -336.82%.
Data updated
Tom Price's BIIB trades vs the price
BIIB is down -15.05% since Tom Price bought on March 17, 2016, versus +321.76% for the S&P 500.
Performance since this trade
All Tom Price BIIB trades
Tom Price & BIIB trading FAQ
Is it legal for Tom Price to trade Biogen Inc (BIIB) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Biogen Inc (BIIB), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Tom Price buy BIIB?
Tom Price disclosed a purchase of $1,001 - $15,000 of Biogen Inc (BIIB) on March 17, 2016, according to public STOCK Act filings.
How has BIIB performed since Tom Price's trade?
Since Tom Price bought BIIB on March 17, 2016, the stock is down -15.05%, versus +321.76% for the S&P 500 over the same period, an outperformance of -336.82%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BIIB trades?
Quantellect tracks every disclosed congressional trade in Biogen Inc (BIIB) on the Biogen Inc congressional trading page, which aggregates filings across all members of Congress.
Tom Price's BIIB tradesAll congressional filings for Biogen IncTom Price's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.